OS Therapies Inc. has announced the development and in vitro concept data for two novel tunable antibody-drug conjugate (tADC) therapeutic candidates leveraging the company’s proprietary Silinker technology.
Medigene AG has obtained FDA clearance of its IND application for lead program MDG-1015 for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Most patients with gastric cancer are diagnosed in advanced stages of the disease. Target identification and unveiling the molecular mechanisms behind it are crucial for this field.
Closely watched-for phase I data from Elevation Oncology Inc. in the Claudin 18.2 space sent shares of the Boston-based firm (NASDAQ:ELEV) down 63%, or $1.35, to close Aug. 6 at 78 cents. Elevation provided initial data from the dose-escalation portion of the ongoing experiment with antibody-drug conjugate (ADC) EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction (GEJ), pancreatic or esophageal cancers.
Researchers from Qingdao University have presented data from a study that aimed to investigate the role of HIG1 hypoxia inducible domain family member 1B (HIGD1B) in gastric cancer (GC). The expression of HIGD1B was analyzed in GC and normal gastric tissues from multiple independent cohorts from public databases and verified using cell experiments.
Investors wanted more from ALX Oncology Holdings Inc.’s phase II study testing evorpacept (evo) combination therapy in gastric tumors, and the stock (NASDAQ:ALXO) tumbled 36% or $1.77 to close Aug. 1 at $3.04.
Astellas Pharma Inc.’s claudin (CLDN) 18.2-targeted monoclonal antibody, zolbetuximab, received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) and could be the first CLDN18.2 molecule to be approved in Europe if it receives final approval.
Astellas Pharma Inc.’s claudin (CLDN) 18.2-targeted monoclonal antibody, zolbetuximab, received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) and could be the first CLDN18.2 molecule to be approved in Europe if it receives final approval.
N6-Methyladenosine (m6A) is the most widely distributed RNA modification in eukaryotes and its dysregulation has been tied in gastric cancer protumorigenic processes, as well as drug resistance and metastasis. Vir-like m6A methyltransferase associated, also known as KIAA1429, is a crucial regulator of the m6A complex, and thus hypothesized to be involved in the progression of gastric cancer.
Researchers from Oricell Therapeutics (Shanghai) Co. Ltd. presented the discovery and preclinical characterization of ORIC-613, a dual-targeting CAR T-cell therapy being developed for the treatment of pancreatic and gastric cancer.
